Table 2.

Relative risk of categorical predictors on development of chemotherapy stoppages or reductions, infections, hospitalizations, and adverse events

Predictor	Chemotherapy stoppage or reduction				Infection				Hospitalization				Adverse event
	No, n (%)	Yes, n (%)	RR	P	No, n (%)	Yes, n (%)	RR	P	No, n (%)	Yes, n (%)	RR	P	No, n (%)	Yes, n (%)	RR	P
Sex
Female	6 (60)	4 (40)		1.00	7 (70)	3 (30)		0.34	6 (60)	4 (40)		1.00	5 (50)	5 (50)		0.37
Male	4 (50)	4 (50)	1.25		3 (38)	5 (63)	2.08		4 (50)	4 (50)	1.25		2 (25)	6 (75)	1.5
A1c <7 at baseline
No	6 (67)	3 (33)	0.53	0.35	4 (44)	5 (56)	2.22	0.33	4 (44)	5 (56)	1.48	0.64	3 (33)	6 (67)	1.33	0.64
Yes	3 (38)	5 (63)	--	--	6 (75)	2 (25)			5 (63)	3 (38)			4 (50)	4 (50)
A1c <7 at 12 weeks
No	4 (57)	3 (43)	0.54	0.29	4 (57)	3 (43)	2.14	0.58	4 (57)	3 (43)	2.14	0.58	3 (43)	4 (57)	1.43	1.00
Yes	1 (20)	4 (80)			4 (80)	1 (20)			4 (80)	1 (20)			3 (60)	2 (40)
On insulin
No	7 (54)	6 (46)		1.00	9 (69)	4 (31)		0.12	9 (69)	4 (31)		0.12	7 (54)	6 (46)		0.10
Yes	3 (60)	2 (40)	0.87		1 (20)	4 (80)	2.60		1 (20)	4 (80)	2.60		0 (0)	5 (100)	2.17
Diabetes <5 years
Yes	2 (40)	3 (60)	1.56	0.61	4 (80)	1 (20)	0.37	0.31	4 (80)	1 (20)	0.37	0.31	4 (80)	1 (20)	0.26	0.047
No	8 (62)	5 (38)	0.64		6 (46)	7 (54)	2.69		6 (46)	7 (54)	2.69		3 (23)	10 (77)	3.85
Diabetes <10 years
Yes	3 (33)	6 (67)	3.00	0.15	6 (67)	3 (33)	0.60	0.64	4 (44)	5 (56)	1.67	0.64	4 (44)	5 (56)	0.83	1.00
No	7 (78)	2 (22)	0.33		4 (44)	5 (56)	1.67		6 (67)	3 (33)	0.60		3 (33)	6 (67)	1.20

*A metric of RR >1.5 or <0.67 was used to identify categorical predictors that merit additional investigation. These items are bolded in the table. RR: Relative risk